Immunother Limited announced today its Research and Development team will collect convalescent plasma from patients previously identified with COVID-19.
Online PR News – 20-May-2021 – SHENZHEN – Immunother Limited will begin the process of clinical trials to research the therapeutic benefit and safety of donated plasma that contains antibodies of SARS-CoV-2 from patients that have previously recovered from COVID-19.
Immunother Limited’s Chairman & Chief Scientist, Mr. Geoffrey Marcus PhD commented on the patient plasma testing saying “In the early days, plasma therapy was commonly used and has had a historical impact on outbreaks of diseases like measles, mumps and influenza, among others and we will use this data to gain extensive knowledge from people who have recovered from COVID-19 to see if their blood can aid us in combatting this deadly virus.”
“In all medical history, it has shown that medical science has the ability to develop powerful therapies that can control and eradicate many deadly viruses and we will trial convalescent plasma for COVID-19 which may be a therapeutic approach for the future. We are very excited to start these clinical research trials and absorb as much knowledge as we can to further prevent any other outbreaks of such viruses,” added Geoffrey Marcus, Chairman & Chief Scientist of Immunother Limited.
About Us - Immunother Limited
Immunother Limited Company is a privately held Shenzhen-based preclinical stage biotechnology company focused on discovering and developing novel therapies for inflammatory diseases.
Immunother Limited Company creates lasting value through pioneering research in the field of immunology which leads to new product concepts, product development, and finally to the licensing of those products and associated intellectual property.